AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04842721
Drug: Hypertonic Saturated Saline Mouth Rinse Active Arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each Patient of this groups will be asked to keep the solution still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the solution will be spit out and mouth will be rinsed with plain water several times. The process will be done twice a day for 2 days.
Trial: NCT05178953
Drug: Zinc Sulfate 220 mg Capsules
RxNorm normalized name: zinc sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc is an element that is involved in the activity of antioxidant enzymes. For example, the superoxide dismutase needs copper and zinc to function properly. Infertile men with asthenospermia receive 220 mg zinc sulfate tablets for 3 months
Trial: NCT04860713
Drug: Nurtec (Rimegepant)
RxNorm normalized name: Nurtec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: 75 mg of ODT
Trial: NCT04368806
Drug: JointStem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous Adipose tissue derived Mesenchymal Stem Cells (AdMSC)
Trial: NCT04906889
Drug: Remifentanil Hydrochloride
RxNorm normalized name: Remifentanil Hydrochloride
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
Trial: NCT05298033
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily vehicle ointment
Trial: NCT05336968
Drug: Triamcinolone acetonide-Ketorolac-Ropivacaine
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental for Osteoarthrosis of the Knee. One randomized injection to intraarticularly into affected knee at time of randomization
Trial: NCT05710692
Drug: PRX-102 1 mg/kg every 2 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRX-102 1 mg/kg every 2 weeks
Trial: NCT05710692
Drug: PRX-102 2 mg/kg every 4 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRX-102 2 mg/kg every 4 weeks
Trial: NCT05288985
Drug: Systemic Analgesia Only Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic analgesia alone consists only of the 3 levels of analgesic treatment
Trial: NCT04961801
Drug: Acalabrutinib, tacrolimus, methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
Trial: NCT06514469
Drug: Sufentanil intravenous administration based on paramedic competency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of sufentanil to patients with acute injury by paramedics based on their competencies
Trial: NCT05756673
Drug: LISTERINE ZERO Alcohol Mouthwash COOL MINT
RxNorm normalized name: Listerine Mouthwash Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will use LISTERINE ZERO Alcohol Mouthwash COOL MINT for 30 second after brushing teeth twice daily.
Trial: NCT05756673
Drug: LISTERINE COOL MINT Antiseptic Mouthwash
RxNorm normalized name: Listerine Cool Mint Antiseptic Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will use LISTERINE COOL MINT Antiseptic Mouthwash for 30 second after brushing teeth twice daily.
Trial: NCT06182072
Drug: ProAgio Dose Levels (DL) 1,2,3,4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic PDAC.
Trial: NCT06674096
Drug: RLC-CRCHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Introduction treatment: Rituximab, lenalidomide, chidamide for 2 cycles:~rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-14, chidamide 20mg, d1,4,8,11.~Immunochemtherapy phase: CR CHOP for 4 cycles: chidamide 20mg d1,4,8,11,rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/ m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5.~maintenance treatment period: chidamide d1,4,8,11
Trial: NCT05362851
Drug: YYC301-1 & YYC301-2 & YYC301-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YYC301-1: Subjects take the investigational products once a day~YYC301-2: Subjects take the investigational products once a day~YYC301-3: Subjects take the investigational products once a day
Trial: NCT04933682
Drug: ALXN2050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet.
Trial: NCT05362851
Drug: YYC301 placebo & Celecoxib 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparator medication
Trial: NCT06184269
Drug: BR1017-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone
Trial: NCT06687174
Drug: MY008211A tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MY008211A BID
Trial: NCT06687174
Drug: MY008211A tablets matched placebo
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to MY008211A taken twice a day.
Trial: NCT06721143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Infusion
Trial: NCT04988087
Drug: MHV370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MHV370 for 24 weeks
Trial: NCT06299514
Drug: Medication
RxNorm normalized name: Acne Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimization of heart failure therapies includes maximum tolerated doses of beta-blockers, aldosterone antagonists, ACE inhibitors, ARB, diuretics, ARNis
Trial: NCT06719700
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide combined with cisplatin or carboplatin, administered every three weeks for a total of four cycles.
Trial: NCT06719700
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab was administered concurrently with chemotherapy, every three weeks for four cycles.
Trial: NCT06224699
Drug: Toothpaste Product
RxNorm normalized name: Toothpaste Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of toothpaste with or without sodium carbonate at 67%
Trial: NCT04885491
Drug: PDNO
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
Trial: NCT06633055
Drug: JH013 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JH013 injection is a BAFF-R inhibitor monoclonal antibody
Trial: NCT06633055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JH013 injections placebo
Trial: NCT01003028
Drug: Remifentanil (Control) - Target Controlled Infusion system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use 20 ng/ml as max plasma concentration
Trial: NCT04841499
Drug: BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take 2 capsules orally each day for 7 days
Trial: NCT06552520
Drug: Placebo of TQH2722 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo without drug substance
Trial: NCT06478758
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The ibuprofen group (n=36) was administered 800 mg of ibuprofen . All procedures were performed with the same team. During surgery, a 20% increase in the participant's heart rate and mean arterial pressure remifentanil infusion was administered. During the postoperative period, all participants continued to receive acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4. In the recovery room, the participants with a visual analog score of \> 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of \> 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.
Trial: NCT06478758
Drug: Acetaminophen 100 MG/ML
RxNorm normalized name: acetaminophen 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigators administered 1000 mg of acetaminophen to the participants in Group A. A 20% increase in the participant's heart rate and mean arterial pressure was evaluated as pain and remifentanil infusion was administered. All participants continued to receive the routine application of acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4, postoperatively.In the recovery room, participants with a visual analog score of \> 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of \> 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.
Trial: NCT04906421
Drug: TVB-2640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose, tablet
Trial: NCT04752332
Drug: Standard Adjuvant ET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to label instructions.
Trial: NCT04752332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05961592
Drug: R-2487
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic
Trial: NCT06462586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsules administered orally, once daily
Trial: NCT06484530
Drug: N acetyl cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 mg/day for 8 weeks in NAT2 gene testing group and NAT2 gene phenotype is identified as slow acetylator.
Trial: NCT03766750
Drug: LIMA association
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 coated tablet, oral, once a day.
Trial: NCT05874401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intravenous placebo infusion
Trial: NCT05360277
Drug: Tislelizumab + Capecitabine
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200mg iv every 3 weeks, for 1 year after completion of perioperative chemotherapy.~Capecitabine was given at a dose of 850 mg/m2 twice a day by mouth, 2 weeks on/ 1 week off, for 1 year after completion of perioperative chemotherapy.
Trial: NCT05256277
Drug: CT101a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cytokine-induced memory-like NK cells
Trial: NCT06338553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule or tablet once before the pre-TZIELD® MMTT and once before one of the post-TZIELD® MMTTs.
Trial: NCT05275777
Drug: ADG106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated.
Trial: NCT05275777
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as an intravenous infusion.
Trial: NCT05275777
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as an intravenous infusion.
Trial: NCT06342804
Drug: 4-MUST, 2 tablets, fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets (256 mg), fasted
Trial: NCT06342804
Drug: 4-MUST, 2 tablets, after meals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets (256 mg), after meals
Trial: NCT05883306
Drug: [14C]LXI-15028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]LXI-15028
Trial: NCT05794516
Drug: ZB004
RxNorm normalized name: Zoledronic acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ZB004 single doses administered subcutaneously as solution
Trial: NCT05794516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single doses administered subcutaneously as solution
Trial: NCT04510194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo; appearance and size are exact matching to the three study drugs.
Trial: NCT05631327
Drug: JZP341
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JZP341 will be administered as a single, intravenous infusion over 2 hours.
Trial: NCT06121557
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered at 500 mg/m\^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
Trial: NCT06121557
Drug: Chemotherapeutic drug, ADC or PARP inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Another anti-tumor drug chosen from chemotherapeutic drug, ADC, or PARP inhibitor will be administered at investigator's discretion.
Trial: NCT04453839
Drug: ZYESAMI (aviptadil acetate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with 12 hour infusions of ZYESAMI at ascending doses of 50/100/150 pmol/kg/hr on 3 or more successive days
Trial: NCT05416697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive 1 droplet of placebo twice daily then titrate up to 2 droplets twice daily if tolerated and continue the treatment until the end of the study.
Trial: NCT04746612
Drug: HH30134
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HH30134 administered orally on a continuous once daily(QD) in patients with advanced solid tumors
Trial: NCT05517603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06512441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group was given a placebo tablet on the same type once a day for 3weeks, besides of the standard IBD treatment.
Trial: NCT05021536
Drug: AMX0035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprietary formulation of taurursodiol and sodium phenylbutyrate
Trial: NCT04775797
Drug: AB-836
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules or Tablets
Trial: NCT04775797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules of Tablets
Trial: NCT04775797
Drug: AB-836
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT04775797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT04775797
Drug: Nucleos(t)ide Analogue
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT05723549
Drug: HCP1803-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once per period
Trial: NCT05723549
Drug: RLD2002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once per period
Trial: NCT05723549
Drug: HCP1904-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once per period
Trial: NCT06232473
Drug: Benztropine Mesylate 0.5 MG and passive placebo RAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Please see arm description
Trial: NCT05392127
Drug: SHR0302 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0302 Tablets once daily
Trial: NCT04684550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
Trial: NCT05835752
Drug: RAY1225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05835752
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04446793
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI (180 mg/m\^2 irinotecan, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil \[5-FU\], and 2400 mg/m\^2 continuous intravenous infusion 5-FU over 46 hours) will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
Trial: NCT05699746
Drug: Capecitabine tablets
RxNorm normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2, twice daily PO for 14 days, repeat every 3 weeks, for at most 8 cycles.
Trial: NCT05804305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contained substance that has no therapeutic value.
Trial: NCT06357806
Drug: NAs
RxNorm normalized name: DNase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT05034484
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered
Trial: NCT05404945
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 25mg/m2 IV
Trial: NCT05508776
Drug: LEO 152020
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film-coated tablet~Route of administration: Orally~50 mg tablets
Trial: NCT05508776
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet~Route of administration: Orally~No active ingredient
Trial: NCT04661930
Drug: TriCor® 145mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate; 145 mg daily (1/day); oral administration; 10 days
Trial: NCT04749979
Drug: Agonist (decapeptyl )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: giving agonist
Trial: NCT05332067
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for omalizumab will be provided in 0.5 mL and 1 mL solution for injection in pre-filled syringes.
Trial: NCT06515652
Drug: rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparing allopathic and herbal group of drugs for metabolic syndrome
Trial: NCT05633576
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of placebo eye drops three times a day for four consecutive weeks.
Trial: NCT05607979
Drug: Lavior Diabetic Wound Gel
RxNorm normalized name: hyaluronate Topical Gel [IPM Wound]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily application of hydrogel treatment for 60 days.
Trial: NCT05913427
Drug: Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Placebo 160 mg tablets will be developed by the CDMO to have the same appearance and taste as the tablet containing the active drug.
Trial: NCT05607979
Drug: Smith & Nephew Solosite Gel Hydrogel Wound Dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily application of hydrogel treatment for 60 days.
Trial: NCT06495307
Drug: rhPRG4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile isotonic aqueous solution containing rhPRG4 (450 µg/mL) for topical administration, 10 mM sodium phosphate, 150 mM sodium chloride \& 0.01% polysorbate 20 at pH 7.2. In all subjects, both eyes will be treated
Trial: NCT05053087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline filled catheter
Trial: NCT03306615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride Injection
Trial: NCT06376604
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles of standard chemotherapy for the gynecologic malignancy.
Trial: NCT05014594
Drug: Placebo of dapaglifozin along with standard medical therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy will include dietary restriction of sodium, treatment with diuretics, repeated LVP as needed and other supportive care. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
Trial: NCT04842292
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized heparin 25,000 units every 6 hours
Trial: NCT04842292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium chloride 0.9% every 6 hours
Trial: NCT05618457
Drug: Aminoglycoside dose adjustment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients may have the aminoglycoside dose adjusted based on pathogen MIC, to attain the PK/PD target of Cam/MIC\~10 (8-12)
Trial: NCT06520176
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1\~Day 2: 1～2g/m\^2
Trial: NCT06430047
Drug: EsoDuo® Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO